The PDE1A-PKCα signaling pathway is involved in the upregulation of α-smooth muscle actin by TGF-β1 in adventitial fibroblasts

Journal of Vascular Research

Volumn 47, Issue 1, 2009, Pages 9-15

  Zhou, Hai Yan ^a   Chen, Wen Dong ^a   Zhu, Ding Liang ^a   Wu, Ling Yun ^a   Zhang, Jia ^a   Han, Wei Qing ^a   Li, Jian Dong ^b   Yan, Chen ^b   Gao, Ping Jin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Smooth muscle actin; Adventitial fibroblasts; Cyclic nucleotide phosphodiesterases; PDE1A; Protein kinase C ; Transforming growth factor 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALPHOSTIN C; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1A; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C ALPHA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; ENZYME ACTIVATOR; NAPHTHALENE DERIVATIVE; PDE1A PROTEIN, RAT; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE INHIBITOR; SMOOTH MUSCLE ACTIN, RAT;

ADVENTITIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME INHIBITION; FIBROBLAST; IMMUNOCYTOCHEMISTRY; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL TRANSDIFFERENTIATION; CONNECTIVE TISSUE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; SPRAGUE DAWLEY RAT;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; CONNECTIVE TISSUE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; ENZYME ACTIVATORS; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; MALE; NAPHTHALENES; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE C-ALPHA; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 68349119096     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000231716     Document Type: Article

References (25)

1. Shi Y, Pieniek M, Fard A, O'Brien J, Mannion JD, Zalewski A: Adventitial remodeling after coronary arterial injury. Circulation 1996; 93:340-348.
2. Shen WL, Gao PJ, Che ZQ, Ji KD, Yin M, Yan C, Berk BC, Zhu DL: NAD(P)H oxidasede-rived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotypic differentiation. Biochem Biophys Res Commun 2006; 339:337-343.
3. Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, Paulet to P: Cont ribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res 2001; 89:1111-1121.
4. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122:103-111.
5. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T: Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001; 163:152-157.
6. Hu B, Wu Z, Phan SH: Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol 2003; 29:397-404.
7. Gao PJ, Li Y, Sun AJ, Liu JJ, Ji KD, Zhang YZ, Sun WL, Marche P, Zhu DL: Differentiation of vascular myofibroblasts induced by transforming growth factor-p1 requires the involvement of protein kinase Ca. J Mol Cell Cardiol 2003; 35:1105-1112.
8. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF: Larginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9:229-244.
9. Chen LL, Yin H, Huang J: Inhibition of TGF-|31 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis. Cardiovasc Pathol 2007; 16:221-230.
10. Nishikimi T, Maeda N, Matsuoka H: The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006; 69:318-328.
11. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y Kangawa K: Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003; 144:2279-2284.
12. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94:453-461.
13. Saura M, Zaragoza C, Herranz B, Griera M, Diez-Marqués L, Rodriguez-Puyol D, Rodriguez-Puyol M: Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ Res 2005; 97:1115-1123.
14. 2+ /calmodul instimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 2006; 98:777-784.
15. Zhu DL, Herembert T, Marche P: Increased proliferation of adventitial fibroblasts from spontaneously hypertensive rat aorta. J Hypertens 1991; 9:1161-1168.
16. Naugle JE, Olson ER, Zhang X, Mase SE, Pi-lati CF, Maron MB, Folkesson HG, Horne WI, Doane KJ, Meszaros JG: Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling. Am J Physiol Heart Circ Physiol 2006; 290: H323-H330.
17. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ: PPAR7 agonists inhibit TGF-|3 induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1146-L1153.
18. Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C: Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 2005; 38:175-184.
19. Wharton J, Strange JW, Møller GM, Grow-cott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR: Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172:105-113.
20. Redondo J, Bishop JE, Wilkins MR: Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol 1998; 124:1455-1462.
21. Evgenov OV, Busch CJ, Evgenov NV, Liu R, Petersen B, Falkowski GE, Petho B, Vas A, Bloch KD, Zapol WM, Ichinose F: Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 290: L723-L729.
22. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA: Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93:280-291.
23. Yan C, Kim D, Aizawa T, Berk BC: Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Ar-terioscler Thromb Vasc Biol 2003; 23:26-36.
24. 2+ channel current in human atrial myocytes. J Physiol 2001; 533:329-340.
25. Sausbier M, Schubert R, Voigt V, Hirneiss C, Pfeifer A, Korth M, Kleppisch T, Ruth P, Hof-mann F: Mechanisms of NO/cGMP-depen-dent vasorela xation. Circ Res 2000; 87:825-830.